Compare Invesco DB Agriculture Fund (DBA) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs DexCom, Inc. — how do they compare? Invesco DB Agriculture Fund trades at $28.33 (market cap $1.32B), while DexCom, Inc. trades at $84.11 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 24.1× Invesco DB Agriculture Fund's market cap, and Invesco DB Agriculture Fund is more actively traded (771,657 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and DexCom, Inc. for 62 Days on average.
| DBA | DXCM | |
|---|---|---|
Market Cap | $1.32B | $31.86B |
Volume | 771,657 | 3,607,070 |
52-Week High | $29.49 | $92.34 |
52-Week Low | $25.44 | $54.84 |
Typical Hold Time | 24 Days | 62 Days |
Sector | — | Health |
Enterprise Value | — | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA trades at $28.34, down 0.53% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has returned 12.4% year-to-date, closely tracking the S&P 500, driven by agricultural commodity strength. Recent news highlights geopolitical catalysts and weather risks as key drivers, while the fund carries a high expense ratio of 0.85%.
Outlook remains mixed; bullish momentum from crop price gains and El Niño risks supports further upside, but high fees and commodity volatility pose headwinds. Investors should weigh diversified agricultural exposure against sector-specific risks and expense drag for balanced portfolio allocation.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
